1. Hasegawa T, Kobayashi J, Ishiyama S. [Emerging disease-modifying strategies targeting α-synuclein in Parkinson’s disease]. Brain Nerve. 2020;72(2):143–50.
2. Nag N, Jelinek GA. A narrative review of lifestyle factors associated with Parkinson’s disease risk and progression. Neurodegener Dis. 2019;19(2):51–9.
3. Amieva H, Meillon C, Proust-Lima C, Dartigues JF. Is low psychomotor speed a marker of brain vulnerability in late life? Digit symbol substitution test in the prediction of Alzheimer, Parkinson, stroke, disability, and depression. Dement Geriatr Cogn Disord. 2019;47(4–6):297–305.
4. Schneider SA, Obeso JA. Clinical and pathological features of Parkinson’s disease. In: Behavioral neurobiology of Huntington’s disease and Parkinson’s disease. Current Topics in Behavioral Neurosciences. Springer; 2014. vol. 22; p. 205–20.
5. Marder K, Tang MX, Mejia H, Alfaro B, Côté L, Louis E, et al. Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology. 1996;47(1):155–60.